Skip to content
CSE: XRX.CN 0.14 0.00 0.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
    • Metabolic Syndrome / Diabetes
    • Hypertension
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Media
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

Reports and Filings

XORTX Financial Statements and MD&A

2018
Q4 Interim Financial Statement

2017

2016

2015

Press Releases

  • XORTX Announces Positive Phase 2 Results in Type 2 Diabetic Nephropathy (T2DN) September 19, 2019
  • XORTX Highlights New Research on Polycystic Kidney Disease Awareness Day September 4, 2019
  • XORTX Announces Virtual Investor Conference Live Webcast July 30, 2019
  • XORTX Reports Annual & Special Meeting Results July 18, 2019
  • XORTX Shares Nature Nephrology Review July 15, 2019
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress